All In Biotech

Drug Trial Radar · NCT03863223

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

A Phase 3,Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy and Safety of Pyrotinib Plus Trastuzumab and Docetaxel Versus Placebo Plus Trastuzumab and Docetaxel in Patients With HER2 Positive MBC.

Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

590

Actual

Start

Apr 22, 2019

Primary completion

Dec 30, 2022

Study completion Jul 30, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Pyrotinib, Trastuzumab, DocetaxelDrug

    Pyrotinib 400mg orally daily until progressive disease

  • Placebo, Trastuzumab, DocetaxelDrug

    Placebo 400mg orally daily until progressive disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: Approximately 42 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital,Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.